JAG
RNAC icon

Journey Advisory Group’s Cartesian Therapeutics RNAC Stock Holding History

Journey Advisory Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-333
Closed -$6.5K – 235
2024
Q1 		$6.5K Sell
333
-167
-33% -$3.54K ﹤0.01% 237
2023
Q4 		$10.3K Sell
500
-333
-40% -$9.94K ﹤0.01% 216
2023
Q3 		$26.5K Hold
833
– – ﹤0.01% 214
2023
Q2 		$28K Buy
+833
New +$29.8K ﹤0.01% 227

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Journey Advisory Group's RNAC Position: Q2 2024 in Review

Journey Advisory Group sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 333 shares — an estimated $6.5K sold.

Journey Advisory Group first reported a position in RNAC in Q2 2023 and held it in 4 quarters. The position peaked at $28K in Q2 2023. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Journey Advisory Group reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Journey Advisory Group sold 333 Cartesian Therapeutics shares in Q2 2024, an estimated $6.5K.
  • Journey Advisory Group first reported a position in Cartesian Therapeutics in Q2 2023 and held it in 4 quarters.
  • Journey Advisory Group's Cartesian Therapeutics position peaked at $28K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Journey Advisory Group's 13F filing for Q2 2024, filed 2 Aug 2024.